CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Glucose dependent insulinotropic polypeptide (GIP)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00774488
NCT00774488N/ACompleted
CompareCT.gov

Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue

German Institute of Human Nutrition·interventional·Posted Oct 17, 2008·Updated Oct 17, 2008

In Brief

A clinical study evaluating Glucose dependent insulinotropic polypeptide (GIP) for Metabolic Syndrome and 2 related conditions. Completed, enrolled 17 participants.

Detailed Summary

This clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon Glucose Dependent Insulinotropic Polypeptide (GIP) on metabolic parameters and gene expression in subcutaneous adipose tissue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Obesity, Insulin Sensitivity
Countries--
CollaboratorsGerman Research Foundation

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2008
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.7 years ago

Interventions

Glucose dependent insulinotropic polypeptide (GIP)other

GIP-Infusions for 4 h in a postprandial concentration